ImmunityBio (IBRX) Stock Forecast & Price Target
Score
ImmunityBio, Inc. price target
| IBRX | |
|---|---|
| Low | $12.00 |
| Average | $14.00 |
| High | $16.00 |
| Upside vs current price | +126.2% |
The average target of $14.00 is +126.2% versus the current IBRX price of $6.19.
ImmunityBio, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
4 analysts cover IBRX.
ImmunityBio, Inc. EPS and revenue estimates
IBRX shows the next fiscal years with at least three analysts: 2026 EPS $-0.96, 2027 EPS $-0.11. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-0.96 | $226.56M |
| 2027 | $-0.11 | $471.90M |
Is ImmunityBio, Inc. a buy or sell?
Of the 4 analysts covering ImmunityBio, Inc., 4 rate it a buy (1 strong buy and 3 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The IBRX consensus label is Buy, beside 4 buy-side ratings and 0 sell-side ratings.
The average target of $14.00 implies +126.2% versus the current price of $6.19.
Those 4 ratings on IBRX are a headcount, and the label on file is Buy.
Reading the ImmunityBio, Inc. forecast
The IBRX target band runs from $12.00 to $16.00. The average inside that band is $14.00.
Set next to the $6.19 IBRX quote, that average is +126.2%.
Ratings on the ImmunityBio, Inc. cluster: 4 of 4 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
IBRX targets have not moved much: $15.00 recently, $15.00 across the quarter.
Only 4 analysts cover IBRX, so the average rests on a short list.
ImmunityBio, Inc. forecast questions
What is the IBRX price target?
The published range for IBRX is $12.00 to $16.00, with an average of $14.00. That average is +126.2% versus the current price of $6.19.
Is ImmunityBio, Inc. a buy or sell?
Of the 4 analysts covering ImmunityBio, Inc., 4 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the IBRX headcount is 4 buy, 0 hold, and 0 sell.
What is the EPS estimate for ImmunityBio, Inc.?
Analyst EPS estimates for ImmunityBio, Inc.: 2026 $-0.96, 2027 $-0.11.
What is the revenue estimate for ImmunityBio, Inc.?
Analyst revenue estimates for ImmunityBio, Inc.: 2026 $226.56M, 2027 $471.90M.
How many analysts cover IBRX?
4 analysts cover IBRX. Their consensus on IBRX is Buy, across those 4.